Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment DOI Open Access
Victoria Serhiyenko, A.A. Serhiyenko

World Journal of Diabetes, Journal Year: 2018, Volume and Issue: 9(1), P. 1 - 24

Published: Jan. 10, 2018

Cardiac autonomic neuropathy (CAN) is a serious com-plication of diabetes mellitus (DM) that strongly associated with approximately five-fold increased risk cardiovascular mortality.CAN manifests in spectrum things, ranging from resting tachycardia and fixed heart rate (HR) to development "silent" myocardial infarction.Clinical correlates or markers for CAN are age, DM duration, glycemic control, hypertension, dyslipidemia (DLP), other microvascular complications.Established factors poor control type 1 combination DLP, obesity, unsatisfactory 2 DM.Symptomatic manifestations include sinus tachycardia, exercise intolerance, orthostatic hypotension (OH), abnormal blood pressure (BP) regulation, dizziness, presyncope syncope, intraoperative instability, asymptomatic ischemia infarction.Methods assessment clinical practice symptoms signs, reflex tests based on HR BP, short-term electrocardiography (ECG), QT interval prolongation, variability (24 h, classic 24 h Holter ECG), ambulatory BP monitoring, turbulence, baroreflex sensitivity, muscle sympathetic nerve activity, catecholamine tests, imaging.Although it common complication, the significance has not been fully appreciated there no unified treatment algorithms today.Treatment early diagnosis, life style changes, optimization management factors.Pathogenetic includes: Balanced diet physical activity; control; DLP; antioxidants, first all α-lipoic acid (ALA), aldose reductase inhibitors, acetyl-L-carnitine; vitamins, fat-soluble vitamin B1; correction vascular endothelial dysfunction; prevention thrombosis; severe cases-treatment OH.The promising methods prescription prostacyclin analogues, thromboxane A2 blockers drugs contribute into strengthening and/or normalization Na + , K -ATPase (phosphodiesterase inhibitor), ALA, dihomo-γ-linolenic (DGLA), ω-3 polyunsaturated fatty acids (ω-3 PUFAs), simultaneous PUFAs DGLA, but future investigations

Language: Английский

American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update DOI
Lawrence Blonde, Guillermo E. Umpierrez,

Sarah Reddy

et al.

Endocrine Practice, Journal Year: 2022, Volume and Issue: 28(10), P. 923 - 1049

Published: Aug. 11, 2022

Language: Английский

Citations

327
Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries DOI
Guy De Backer, Piotr Jankowski, Kornelia Kotseva

et al.

Atherosclerosis, Journal Year: 2019, Volume and Issue: 285, P. 135 - 146

Published: April 24, 2019

Language: Английский

Citations

300
Diabetes and lipid metabolism DOI Open Access
Vasilios G. Athyros, Michael Doumas, Κonstantinos Imprialos

et al.

HORMONES, Journal Year: 2018, Volume and Issue: 17(1), P. 61 - 67

Published: March 1, 2018

Language: Английский

Citations

296
Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease DOI
Erin D. Michos, John W. McEvoy, Roger S. Blumenthal

et al.

New England Journal of Medicine, Journal Year: 2019, Volume and Issue: 381(16), P. 1557 - 1567

Published: Oct. 16, 2019

Management of serum cholesterol level is a central objective in preventing cardiovascular events. Current guidelines recommend calculation risk, with treatment decisions based on these data and clinician–patient discussion risk. Statins remain the first line pharmacotherapy.

Language: Английский

Citations

291
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary DOI Open Access

Alan J. Garber,

Martin J. Abrahamson, Joshua I. Barzilay

et al.

Endocrine Practice, Journal Year: 2019, Volume and Issue: 25(1), P. 69 - 101

Published: Jan. 1, 2019

Language: Английский

Citations

285
Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors DOI Open Access
Alex H. Krist, Karina W. Davidson, Carol M. Mangione

et al.

JAMA, Journal Year: 2020, Volume and Issue: 324(20), P. 2069 - 2069

Published: Nov. 24, 2020

Cardiovascular disease (CVD) is a leading cause of death in the US. Known modifiable risk factors for CVD include smoking, overweight and obesity, diabetes, elevated blood pressure or hypertension, dyslipidemia, lack physical activity, unhealthy diet. Adults who adhere to national guidelines healthy diet activity have lower cardiovascular morbidity mortality than those do not. All persons, regardless their status, benefit from eating behaviors appropriate activity.To update its 2014 recommendation, USPSTF commissioned review evidence on behavioral counseling promote prevention adults with factors.This recommendation statement applies 18 years older known hypertension pressure, mixed multiple such as metabolic syndrome an estimated 10-year 7.5% greater. other abnormal glucose levels, smoking are not included this recommendation.The concludes moderate certainty that interventions net at increased CVD.The recommends offering referring activity. (B recommendation).

Language: Английский

Citations

264
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial DOI

Kausik K Ray,

Helen M Colhoun,

Michael Szarek

et al.

The Lancet Diabetes & Endocrinology, Journal Year: 2019, Volume and Issue: 7(8), P. 618 - 628

Published: July 1, 2019

Language: Английский

Citations

262
Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures – 2019 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists DOI
Jeffrey I. Mechanick,

Caroline M. Apovian,

Stacy A. Brethauer

et al.

Obesity, Journal Year: 2020, Volume and Issue: 28(4)

Published: March 23, 2020

Objective The development of these updated clinical practice guidelines (CPGs) was commissioned by the American Association Clinical Endocrinologists (AACE), Obesity Society (TOS), for Metabolic and Bariatric Surgery (ASMBS), Medicine (OMA), Anesthesiologists (ASA) Boards Directors in adherence with AACE 2017 protocol standardized production CPGs, algorithms, checklists. Methods Each recommendation evaluated based on new evidence from 2013 to present subjective factors provided experts. Results New or topics this CPG include: contextualization an adiposity‐based chronic disease complications‐centric model, nuance‐based algorithm/checklist‐assisted decision‐making about procedure selection, novel bariatric procedures, enhanced recovery after surgery protocols, logistical concerns (including cost factors) current health care arena. There are 85 numbered recommendations that have supporting evidence, which 61 revised 12 new. Noting there can be multiple statements within a single recommendation, 31 (13%) Grade A, 42 (17%) B, 72 (29%) C, 101 (41%) D recommendations. 858 citations, 81 (9.4%) level (EL) 1 (highest), 562 (65.5%) EL 2, (8.4%) 3, 143 (16.7%) 4 (lowest). Conclusions procedures remain safe effective intervention higher‐risk patients obesity. should context disease. A team approach perioperative is mandatory, special attention nutritional metabolic issues.

Language: Английский

Citations

248
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM DOI Creative Commons

Michel R. Langlois,

M. John Chapman, Christa M. Cobbaert

et al.

Clinical Chemistry, Journal Year: 2018, Volume and Issue: 64(7), P. 1006 - 1033

Published: May 14, 2018

The European Atherosclerosis Society-European Federation of Clinical Chemistry and Laboratory Medicine Consensus Panel aims to provide recommendations optimize atherogenic lipoprotein quantification for cardiovascular risk management.We critically examined LDL cholesterol, non-HDL apolipoprotein B (apoB), particle number assays based on key criteria medical application biomarkers. (a) Analytical performance: Discordant cholesterol occurs when is measured or calculated with different assays, especially in patients hypertriglyceridemia >175 mg/dL (2 mmol/L) low concentrations <70 (1.8 mmol/L). Increased lipoprotein(a) should be excluded not achieving goals treatment. Non-HDL includes the component remnant can a standard nonfasting lipid panel without additional expense. ApoB more accurately reflects number. (b) apoB are comparable predictors events prospective population studies clinical trials; however, discordance analysis markers improves prediction by adding (included cholesterol) (with apoB) components testing. (c) cost-effectiveness: There no consistent evidence yet that cholesterol-, apoB-, particle-targeted treatment reduces healthcare-related costs than targeted cholesterol.Follow-up pre- on-treatment (measured calculated) concentration patient ideally performed same documented test method. (or secondary target mild moderate hypertriglyceridemia, whom measurement calculation less accurate often predictive risk. Laboratories report all panels.

Language: Английский

Citations

230
Decision tree-based diagnosis of coronary artery disease: CART model DOI
Mohammad M. Ghiasi, Sohrab Zendehboudi,

Ali Asghar Mohsenipour

et al.

Computer Methods and Programs in Biomedicine, Journal Year: 2020, Volume and Issue: 192, P. 105400 - 105400

Published: Feb. 19, 2020

Language: Английский

Citations

229